NetworkNewsBreaks

TuesdayAug 15, 2023 1:08 pm

NetworkNewsBreaks – GRN Holding Corporation (GRNF), One World Legends Enter Strategic Joint Venture

GRN Holding Corporation (OTC: GRNF) and Marijuana Inc., having recently merged into a consolidated entity, today announced a joint venture with One World Legends (“OWL”), a distinguished player in the cannabis sector. The partnership marks a significant step forward in shaping the future of the cannabis industry and fostering innovation, growth and global collaboration. “We have been working with One World Legends for two years on this project. The joint venture signifies a powerful fusion of expertise, vision and dedication,” said Donald Steinberg, CEO of Marijuana Inc. “OWL has a selection of 17 Landrace strains, which include some famous old…

Continue Reading

TuesdayAug 15, 2023 1:02 pm

NetworkNewsBreaks – GEMXX Corporation (GEMZ) Releases Report of First 2023 Season Gold Production from Snow Creek Mine Site

GEMXX (OTC: GEMZ), a leader in the Ammolite gemstone mine-to-market segment, is reporting the successful completion of its first clean-out and recording of gold production at the Snow Creek Mine site for the 2023 mining season. GEMXX is working in collaboration with Crazy Horse Mining Inc. (“CHMI”) on the Snow Creek Mine project. According to the announcement, the two companies have processed a 4,500-cubic-yard sample of gold-bearing surface ore stockpiled while building the processing site, thereby providing a “positive indication of the resource potential on the property.” The company noted that initial production results, which have yielded 38.73 ounces of…

Continue Reading

TuesdayAug 15, 2023 12:50 pm

NetworkNewsBreaks – Correlate Energy Corp. (CIPI) Announces Strong Q2 Results, Eyes Growing Momentum

Correlate (OTCQB: CIPI), a growth-oriented distributed energy company, has announced financial results for the second quarter ended June 30, 2023. Among the highlights, the company reported that it achieved revenue of $4,158,122 in Q2 2023 compared to $236,690 for the same quarter last year. Correlate believes that demand for renewables will continue to grow exponentially and that the need for localized energy systems that can operate independently or in connection with the main power infrastructure, such as microgrids, will play a pivotal role in facilitating the ongoing transition to renewable energy in the United States. “Correlate Energy Corp. is led…

Continue Reading

TuesdayAug 15, 2023 12:39 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that its late breaking abstract about phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for Oct. 11-13, 2023. “We are excited about presenting our phase 1 first-in-human clinical data on Lucid-MS at this peer conference in Milan,” said Andrzej Chruscinski, M.D., Ph.D., VP, clinical and scientific affairs, Lucid Psycheceuticals. “Current…

Continue Reading

MondayAug 14, 2023 2:41 pm

NetworkNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Q2 2023 Results, Strategic Business Review Update

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to extend runway, optimize marketing mix, and support business development efforts. While this streamlining had a modest unfavorable impact on sales during the quarter, we have gained greater conviction that driving consumer awareness is the next…

Continue Reading

MondayAug 14, 2023 2:26 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Continues Sales Momentum with Three New Contracts, Takes Roadshow to Pittsburg

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is seeing consistent rising sales; the company just announced the signing of three more contracts. According to the announcement, Knightscope has inked security deals with a third-party logistics (“3PL”) provider in the Midwest; a Central-U.S. regional transit authority and a country club in the Northeast. According to the announcement, the regional 3PL provider is a current KSCP customer that signed its first Knightscope contract last year. The company offers value-added services such as warehousing and distribution, packaging, assembly, and fulfillment and has facilities…

Continue Reading

MondayAug 14, 2023 2:15 pm

NetworkNewsBreaks – LQR House Inc. (NASDAQ: LQR) Closes on $5.75M Initial Public Offering

LQR House (NASDAQ: LQR), a company that intends to become the full-service digital marketing and brand-development face of the alcoholic beverage space, has closed on its initial public offering. The offering was comprised of 1 million shares of common stock, offered at $5 per share. According to the announcement, the underwriters exercised their overallotment option in full, resulting in an additional 150,000 shares of common stock at the time of the closing. Gross proceeds from the public offering, including overallotments, totaled approximately $5.75 million, before the deduction of any underwriting discounts or offering expenses. EF Hutton, a division of Benchmark…

Continue Reading

MondayAug 14, 2023 2:03 pm

NetworkNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, is reporting on its financial and business results for the first quarter of the 2024 fiscal year, the period ended June 30, 2023. Highlights of the report include a 161% increase in net revenue, which totaled approximately $555,000 compared to $212,000 in the same quarter of 2023; continued momentum in the development of IGC’s phase 3 manufacturing facility located on the West Coast; a $12 million line…

Continue Reading

MondayAug 14, 2023 1:39 pm

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Fiscal Q3 Results, Business Update

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced financial results for its fiscal third quarter for the three and nine months ended June 30, 2023, and provided recent business updates. Among the highlights, the company’s board of directors has authorized a stock buyback program, pursuant to which the company may, until Dec. 31, 2023, purchase up to $25 million in shares of its outstanding common stock. Mullen ended fiscal third quarter on June 30, 2023, with stockholders’ equity of $351.8 million, compared to $157.0 million on Sept 30, 2022, which represents a 124% increase. In addition,…

Continue Reading

MondayAug 14, 2023 12:53 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date since we launched CNS Pharma. We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach…

Continue Reading